High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
08
2019
accepted:
02
12
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Pancreatic cancer has an extremely poor prognosis, and identification of novel predictors of therapeutic efficacy and prognosis is urgently needed. Chemoresistance-related molecules are correlated with poor prognosis and may be effective targets for cancer treatment. Here, we aimed to identify novel molecules correlated with chemoresistance and poor prognosis in pancreatic cancer. We established 10 patient-derived xenograft (PDX) lines from patients with pancreatic cancer and performed next-generation sequencing (NGS) of tumor tissues from PDXs after treatment with standard drugs. We established a gene-transferred tumor cell line to express chemoresistance-related molecules and analyzed the chemoresistance of the established cell line against standard drugs. Finally, we performed immunohistochemical (IHC) analysis of chemoresistance-related molecules using 80 pancreatic cancer tissues. From NGS analysis, we identified olfactomedin-4 (OLFM4) as having high expression in the PDX group treated with anticancer drugs. In IHC analysis, OLFM4 expression was also high in PDXs administered anticancer drugs compared with that in untreated PDXs. Chemoresistance was observed by in vitro analysis of tumor cell lines with forced expression of OLFM4. In an assessment of tissue specimens from 80 patients with pancreatic cancer, Kaplan-Meier analysis showed that patients in the low OLFM4 expression group had a better survival rate than patients in the high OLFM4 expression group. Additionally, multivariate analysis showed that high expression of OLFM4 was an independent prognostic factor predicting poor outcomes. Overall, our study revealed that high expression of OLFM4 was involved in chemoresistance and was an independent prognostic factor in pancreatic cancer. OLFM4 may be a candidate therapeutic target in pancreatic cancer.
Identifiants
pubmed: 31923206
doi: 10.1371/journal.pone.0226707
pii: PONE-D-19-18437
pmc: PMC6953839
doi:
Substances chimiques
OLFM4 protein, human
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0226707Déclaration de conflit d'intérêts
The authors have read the journal’s policy and the authors of this paper have the following competing interests: HI is paid employees of Noile-Immune Biotech, Inc., clinical stage biotechnology company. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Proteomics Clin Appl. 2015 Feb;9(1-2):58-63
pubmed: 25400027
World J Gastroenterol. 2018 May 7;24(17):1881-1887
pubmed: 29740203
Cancer Sci. 2018 Oct;109(10):3350-3359
pubmed: 30137688
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Am J Pathol. 2013 Oct;183(4):1329-38
pubmed: 24070418
J Cancer Res Clin Oncol. 2011 Nov;137(11):1713-20
pubmed: 21904905
Mol Cells. 2016 Feb;39(2):77-86
pubmed: 26831452
Nature. 2013 Jul 4;499(7456):79-82
pubmed: 23676674
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
Carcinogenesis. 2011 Jul;32(7):986-94
pubmed: 21470957
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Clin Cancer Res. 2011 May 15;17(10):3146-56
pubmed: 21447729
J Biol Chem. 2000 Oct 27;275(43):33416-26
pubmed: 10924506
Int J Cancer. 2013 Mar 15;132(6):1368-82
pubmed: 22915188
Nat Protoc. 2007;2(2):247-50
pubmed: 17406581
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Virchows Arch. 2015 Sep;467(3):285-94
pubmed: 26070873
Nat Rev Cancer. 2003 Apr;3(4):267-75
pubmed: 12671665
Histopathology. 2007 Aug;51(2):157-65
pubmed: 17650212
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
BMC Genomics. 2016 Nov 9;17(1):899
pubmed: 27829362
Nature. 2016 Feb 25;530(7591):391
pubmed: 26911756
Int J Gynecol Cancer. 2011 Feb;21(2):367-72
pubmed: 21270618
Cancer Metastasis Rev. 2010 Dec;29(4):761-75
pubmed: 20878207
Br J Cancer. 2001 May 18;84(10):1424-31
pubmed: 11355958
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Hum Pathol. 2015 May;46(5):732-8
pubmed: 25771901
Pancreas. 2004 Apr;28(3):219-30
pubmed: 15084961
Mol Biosyst. 2009 Dec;5(12):1512-26
pubmed: 20023718
Ann Surg. 2003 Jan;237(1):74-85
pubmed: 12496533
Exp Ther Med. 2010 Jan;1(1):73-78
pubmed: 23136596
Clin Cancer Res. 2008 Feb 15;14(4):1041-9
pubmed: 18281536
J Cell Mol Med. 2014 May;18(5):863-74
pubmed: 24495253
Biomed Pharmacother. 2017 Feb;86:67-73
pubmed: 27939521
Int J Oncol. 2015 Jul;47(1):61-70
pubmed: 25963555
Future Sci OA. 2017 Dec 07;4(3):FSO271
pubmed: 29568561
Mol Carcinog. 2010 Mar;49(3):259-70
pubmed: 19908244
Oncotarget. 2016 Mar 1;7(9):10594-605
pubmed: 26871282
Cancer Res. 2004 Apr 1;64(7):2474-81
pubmed: 15059901
Hepatogastroenterology. 2011 Jul-Aug;58(109):1354-9
pubmed: 21937407
Exp Cell Res. 2006 Jun 10;312(10):1785-97
pubmed: 16566923
Cancer Sci. 2007 Mar;98(3):334-40
pubmed: 17270022
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
PLoS One. 2011;6(12):e28384
pubmed: 22164281
Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354
pubmed: 16585151
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
J Interferon Cytokine Res. 2000 Jul;20(7):661-5
pubmed: 10926209
Proteomics. 2011 Feb;11(4):816-28
pubmed: 21229586
Development. 2012 Feb;139(3):488-97
pubmed: 22190634